Preferred Label : letermovir;

Details


Main resources

You can consult :


https://www.has-sante.fr/portail/jcms/c_2869231/fr/prevymis
2018
false
false
false
France
French
treatment outcome
orphan drug production
hematopoietic stem cell transplantation
allografts
Allogeneic Hematopoietic Stem Cell Transplantation
antiviral agents
cytomegalovirus infections
Cytomegalovirus infection reactivation
administration, oral
infusions, intravenous
terminase
enzyme inhibitors
letermovir
adult
aged
evaluation of the transparency committee
insurance, health, reimbursement
letermovir
letermovir
acetates
quinazolines
endodeoxyribonucleases

---
Prevymis letermovir
https://www.ema.europa.eu/medicines/human/EPAR/Prevymis
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
letermovir
drug approval
europe
treatment outcome
orphan drug production
hematopoietic stem cell transplantation
allografts
Allogeneic Hematopoietic Stem Cell Transplantation
antiviral agents
antiviral agents
cytomegalovirus infections
Cytomegalovirus infection reactivation
administration, oral
infusions, intravenous
terminase
enzyme inhibitors
enzyme inhibitors
pregnancy
breast feeding
drug interactions
letermovir
product surveillance, postmarketing
adult
aged
drug evaluation, preclinical
letermovir
letermovir
acetates
quinazolines
letermovir
endodeoxyribonucleases
acetates
quinazolines

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.